了解糖尿病肾病中的分子失调，以确定新的靶点和治疗机会。
Understanding molecular upsets in diabetic nephropathy to identify novel targets and treatment opportunities.
机构信息
National Institute of Pharmaceutical Education and Research (NIPER) Ahmedabad, An Institute of National Importance, Government of India, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Palaj, Opp. Air Force Station, Gandhinagar 382355, Gujarat, India.
National Institute of Pharmaceutical Education and Research (NIPER) Ahmedabad, An Institute of National Importance, Government of India, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Palaj, Opp. Air Force Station, Gandhinagar 382355, Gujarat, India; Indian Institute of Technology-Jammu, Jagti, PO Nagrota, Jammu 181 221, J&K, India.
出版信息
Drug Discov Today. 2020 May;25(5):862-878. doi: 10.1016/j.drudis.2020.01.008. Epub 2020 Jan 22.
Diabetes and related complications are becoming a global encumbrance. Diabetic nephropathy (DN) is a major cause of end-stage renal disease (ESRD). The available therapeutic modalities related to DN do not treat DN at the molecular level, proposing further amendments in the management of DN based on the pathogenesis of DN. This manuscript discusses the concept and applications of nanomedicine for the treatment of DN that can improve renal targeting, retention and localization. This review also highlights the current issues related to targeting DN, challenges and allied opportunities toward the development of next-generation drugs and treatments for the management of DN.
糖尿病及其相关并发症正成为全球性负担。糖尿病肾病（DN）是终末期肾病（ESRD）的主要原因。现有的与 DN 相关的治疗方法并不能在分子水平上治疗 DN，因此需要根据 DN 的发病机制对其进行进一步的治疗修正。本文讨论了纳米医学治疗 DN 的概念和应用，这些方法可以改善肾脏的靶向性、滞留性和定位性。本文还强调了与靶向 DN 相关的当前问题、挑战以及开发新一代药物和治疗方法来管理 DN 的联合机遇。
Zotero 插件